Journey Medical CorporationDERMNASDAQ
Loading
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive growthDecelerating
Average
6.14%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | -82.11% |
| Q4 2024 | -74.11% |
| Q3 2024 | -7.78% |
| Q2 2024 | -88.42% |
| Q1 2024 | 423.85% |
| Q4 2023 | -32.48% |
| Q3 2023 | 25.65% |
| Q2 2023 | -12.74% |
| Q1 2023 | -52.23% |
| Q4 2022 | 51.35% |
| Q3 2022 | 7.78% |
| Q2 2022 | 106.08% |
| Q1 2022 | -36.45% |
| Q4 2021 | 150.88% |
| Q3 2021 | -94.23% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |
| Q3 2019 | 0.72% |
| Q2 2019 | 17.44% |
| Q1 2019 | -18.57% |
| Q4 2018 | 17.35% |
| Q3 2018 | -16.64% |
| Q2 2018 | -23.63% |
| Q1 2018 | -7.89% |
| Q4 2017 | -9.76% |
| Q3 2017 | 18.52% |
| Q2 2017 | 30.81% |
| Q1 2017 | -4.79% |
| Q4 2016 | 17.30% |
| Q3 2016 | -17.93% |
| Q2 2016 | -5.19% |
| Q1 2016 | -6.17% |
| Q4 2015 | 28.95% |
| Q3 2015 | 39.98% |